Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial

医学 败血症 打开标签 敌手 麻醉 随机对照试验 内科学 药理学 受体
作者
Yasuyuki Kakihana,Osamu Nishida,Takumi Taniguchi,Masaki Okajima,Hiroshi Morimatsu,Hiroshi Ogura,Yoshitsugu Yamada,Tetsuji Nagano,Eiichiro Morishima,Naoyuki Matsuda
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:8 (9): 863-872 被引量:153
标识
DOI:10.1016/s2213-2600(20)30037-0
摘要

Tachycardia and atrial fibrillation frequently occur in patients being treated for sepsis or septic shock and have a poor prognosis. Treatments for tachyarrhythmias are often ineffective or contraindicated in this setting. We aimed to investigate the efficacy and safety of landiolol, an ultra-short-acting β-blocker, for treating sepsis-related tachyarrhythmias.We did a multicentre, open-label, randomised controlled trial at 54 hospitals in Japan. Patients admitted to the intensive care units who received conventional treatment for sepsis, according to clinical guidelines for the management of sepsis, and who subsequently developed a tachyarrhythmia, were enrolled. The main inclusion criteria were 20 years of age or older, diagnosis of sepsis according to Third International Consensus Definitions for Sepsis and Septic Shock criteria, administration of catecholamine necessary to maintain mean arterial pressure at 65 mm Hg or more for at least 1 h, and heart rate of 100 beats per min (bpm) or more maintained for at least 10 min without a change in catecholamine dose with diagnosis of atrial fibrillation, atrial flutter, or sinus tachycardia. Only patients who developed these symptoms and signs within 24 h before randomisation, and within 72 h after entering an intensive care unit, were prospectively assigned to receive conventional sepsis therapy alone (control group) or conventional sepsis therapy plus landiolol (landiolol group) in an open-label manner. Landiolol hydrochloride was intravenously infused at an initial dose of 1 μg/kg per min within 2 h after randomisation and the dose could be increased per study protocol to a maximum of 20 μg/kg per min. Patients in both groups received conventional therapy (Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2016), including respiratory and fluid resuscitation, antimicrobials, and catecholamines. The treating physicians were required to stabilise the patient's haemodynamic status before randomisation. Randomisation was done using a central randomisation system and dynamic allocation with the minimisation method by institution, heart rate at randomisation (≥100 to <120 bpm or ≥120 bpm), and age (<70 years or ≥70 years). The primary outcome was the proportion of patients with heart rate of 60-94 bpm at 24 h after randomisation. Patients without heart rate data at 24 h after randomisation were handled as non-responders. The primary outcome was analysed using the full analysis set on an as-assigned basis, while safety was analysed using the safety analysis set according to the treatment received. This study was registered with the Japan Pharmaceutical Information Center Clinical Trials Information database, number JapicCTI-173767.Between Jan 16, 2018 and Apr 22, 2019, 151 patients were randomly assigned, 76 to the landiolol group and 75 to the control group. A significantly larger proportion of patients in the landiolol group had a heart rate of 60-94 bpm 24 h after randomisation than in the control group (55% [41 of 75] vs 33% [25 of 75]), with a between-group difference of 23·1% (95% CI 7·1-37·5; p=0·0031). Adverse events were observed in 49 (64%) of 77 patients in the landiolol group and in 44 (59%) of 74 in the control group, with serious adverse events (including adverse events leading to death) in nine (12%) of 77 and eight (11%) of 74 patients. Serious adverse events related to landiolol occurred in five (6%) of 77 patients, including blood pressure decreases in three patients (4%) and cardiac arrest, heart rate decrease, and ejection fraction decrease occurred in one patient each (1%).Landiolol resulted in significantly more patients with sepsis-related tachyarrhythmia achieving a heart rate of 60-94 bpm at 24 h and significantly reduced the incidence of new-onset arrhythmia. Landiolol was also well tolerated, but it should be used under appropriate monitoring of blood pressure and heart rate owing to the risk of hypotension in patients with sepsis and septic shock.Ono Pharmaceutical Co.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
ZGD完成签到 ,获得积分10
1秒前
桃子发布了新的文献求助10
2秒前
west完成签到,获得积分10
2秒前
徐师傅完成签到,获得积分10
2秒前
小二郎的应助被312采纳,获得10
4秒前
大模型的应助被so采纳,获得10
4秒前
4秒前
章鱼小丸子完成签到 ,获得积分10
5秒前
5秒前
左旋多巴完成签到,获得积分0
5秒前
qwzh完成签到,获得积分10
5秒前
水煮电吹风的应助被hc采纳,获得10
5秒前
lydia完成签到,获得积分10
6秒前
活泼糜发布了新的文献求助10
6秒前
6秒前
6秒前
大东东完成签到,获得积分10
6秒前
7秒前
无心的小凡完成签到,获得积分10
7秒前
科研通AI2S的应助被zz采纳,获得10
7秒前
7秒前
闪闪新晴发布了新的文献求助30
7秒前
小雪要上岸完成签到,获得积分10
7秒前
7秒前
晨儿完成签到 ,获得积分10
8秒前
所所的应助被随意采纳,获得10
9秒前
9秒前
阔达的皮皮虾完成签到,获得积分10
9秒前
远方发布了新的文献求助10
10秒前
11秒前
ali8ba发布了新的文献求助10
12秒前
科研通AI2S的应助被简朴煜城采纳,获得10
12秒前
12秒前
LSF关注了科研通微信公众号
12秒前
受伤白安发布了新的文献求助10
12秒前
yjx完成签到,获得积分10
12秒前
F_ken完成签到,获得积分10
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182147
求助须知:如何正确求助?哪些是违规求助? 9571790
关于积分的说明 21820037
捐赠科研通 7778601
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479652